// App-Quantinova.ai

15586 : Burden of Cardiovascular or Fatal Outcomes in People With Type 2 Diabetes and Cardiovascular Risk Factors Treated With Dulaglutide a Post Hoc Analysis From the Rewind Trial

Researchers

Presenter

  • Gilles Dagenais

Principal Investigators

  • Mark C Lakshmanan

  • Leanne Dyal

  • Charles Messan Atisso

  • Helen Colhoun

  • Lars E Ryden

  • Hertzel C Gerstein

Medical Centers

  • IUCPQ, Quebec, QC, Canada

  • Lilly Corporate Cntr, Eli Lilly and company, Indianapolis, IN

  • Statistics, Population Health Rsch Institute, Hamilton, Canada

  • Eli Lilly, Indianapolis, IN

  • Molecular Genetic and Population Health Science, Univ of Edimburgh, Edimburgh, United Kingdom

  • FoU- Tema Hjärta Kärl S1:02, Stockholm, Sweden

  • McMaster University, Hamilton, ON, Canada

Locations

  • Canada

  • United States

  • United Kingdom

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Type 2 diabetes mellitus

Biomarkers

  • N/A

Drug/Treatment

  • Dulaglutide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01394952

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved